US20080177373A1 - Endoprosthesis structures having supporting features - Google Patents

Endoprosthesis structures having supporting features Download PDF

Info

Publication number
US20080177373A1
US20080177373A1 US12/016,077 US1607708A US2008177373A1 US 20080177373 A1 US20080177373 A1 US 20080177373A1 US 1607708 A US1607708 A US 1607708A US 2008177373 A1 US2008177373 A1 US 2008177373A1
Authority
US
United States
Prior art keywords
endoprosthesis
supporting
struts
rings
serpentine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/016,077
Other languages
English (en)
Inventor
Howard Huang
John Yan
Brett Cryer
Motasim Sirhan
Vinayak Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elixir Medical Corp
Original Assignee
Elixir Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39636746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080177373(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/016,077 priority Critical patent/US20080177373A1/en
Application filed by Elixir Medical Corp filed Critical Elixir Medical Corp
Assigned to ELIXIR MEDICAL CORPORATION reassignment ELIXIR MEDICAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRYER, BRETT, SIRHAN, MOTASIM, BHAT, VINAYAK, HUANG, HOWARD, YAN, JOHN
Publication of US20080177373A1 publication Critical patent/US20080177373A1/en
Priority to US13/536,957 priority patent/US20130150943A1/en
Priority to US13/539,770 priority patent/US8636792B2/en
Priority to US13/897,302 priority patent/US8814930B2/en
Priority to US14/097,087 priority patent/US20140188243A1/en
Assigned to ELIXIR MEDICAL CORPORATION, A CALIFORNIA CORPORATION reassignment ELIXIR MEDICAL CORPORATION, A CALIFORNIA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ELIXIR MEDICAL CORPORATION, A DELAWARE CORPORATION
Priority to US14/461,159 priority patent/US9119905B2/en
Priority to US14/604,621 priority patent/US20160213499A1/en
Priority to US14/611,043 priority patent/US20150374521A1/en
Priority to US14/804,415 priority patent/US9566371B2/en
Priority to US15/178,506 priority patent/US20160278953A1/en
Priority to US15/420,615 priority patent/US20170156899A1/en
Priority to US15/900,404 priority patent/US20200093619A1/en
Priority to US17/709,116 priority patent/US20240074882A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/823—Stents, different from stent-grafts, adapted to cover an aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2002/825—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having longitudinal struts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0004—Rounded shapes, e.g. with rounded corners
    • A61F2230/0013—Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0036—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in thickness
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
    • Y10T428/139—Open-ended, self-supporting conduit, cylinder, or tube-type article

Definitions

  • the present invention relates to endoprosthesis designs, in particular biodegradable and non-biodegradable stents and grafts, which are adapted to be implanted into a patient's body lumen, such as coronary artery or other blood vessel or body lumen. Stents are particularly useful in the treatment of atherosclerotic stenosis in arteries and veins.
  • Stents are generally tubular-shaped devices which function to hold open or reinforce a segment of a blood vessel or other body lumen such as a coronary artery, carotid artery, saphenous vein graft, or femoral artery. They also are suitable to support and hold back a dissected arterial lining that can occlude the fluid passageway, to stabilize plaque, or to support bioprosthetic valves. Stents can be formed from various materials, particularly polymeric and/or metallic materials, and may be non-degradable, biodegradable, or be formed from both degradable and non-degradable components. Stents are typically delivered to the target area within the body lumen using a catheter.
  • the stent With balloon-expandable stents, the stent is mounted to a balloon catheter, navigated to the appropriate area, and the stent expanded by inflating the balloon. A self-expanding stent is delivered to the target area and released, expanding to the required diameter to treat the disease. Stents may also elute various drugs and pharmacological agents.
  • a common pattern employed in present cardiovascular stents comprises a plurality of serpentine rings 12 joined by short axial links 14 .
  • the serpentine rings comprise axial struts 16 , where circumferentially adjacent struts are connected by crowns 18 which act as hinges in permitting circumferential expansion of the individual rings 12 .
  • crowns 18 which act as hinges in permitting circumferential expansion of the individual rings 12 .
  • stents and other endoprostheses In the design of stents and other endoprostheses, a number of competing objectives must be addressed. For coronary artery stents, it is usually desirable to be able to collapse the stent to minimize the cross-sectional area for delivery while maximizing the surface area of the stent after expansion. A maximized surface area provides both enhanced wall support to reduce vessel recoil and a greater capacity to deliver drugs when employing drug-coated stents. A further design objective is to allow the stent to be compressed with a minimum force while still maintaining a good hoop strength after expansion to further resist vessel recoil.
  • a stent design or stent material which enhances radial or hoop strength, reduces vessel recoil after implantation, provides an increased surface area while maintaining or reducing the size and mass of the stent.
  • the present invention meets at least some of these requirements.
  • U.S. Pat. No. 6,773,455 describes a stent having serpentine rings axially connected via internal expansion elements.
  • US 2003/0093143 describes a stent comprising box structures joined circumferentially by U-shaped connectors.
  • US2003/0144729 describes a stent comprising axially spaced serpentine bands connected by wishbone connectors. See also U.S. Pat. No. 7,291,166 and U.S. Pat. No. 6,896,695.
  • the present invention provides an endoprosthesis, such as a stent, graft or other scaffold-like luminal prosthesis, that is used for treating vascular and other luminal conditions.
  • the endoprosthesis includes supporting features or elements added to a base structure.
  • the base structure of the stent is formed from a series of circumferential serpentine rings connected directly to each other or with at least one link or strut, generally as shown in FIG. 1 discussed above, where each ring comprises multiple expansion segments constructed from crowns and struts.
  • the base structure is reinforced with supporting features which can increase radial strength and/or reduce recoil upon expansion of the stent compared to the structure without the supporting features.
  • the supporting features can contain varying types of shapes such as an I-shape, C-shape, V-shape, U-shape, S-shape, Y-shape, M-shape, W-shape, Z-shape, spiral-shape or other types.
  • the supporting features connect at least some of the adjacent struts.
  • at least one supporting feature connects to at least one axially connecting link.
  • an endoprosthesis comprises a plurality of circumferentially expandable serpentine rings, axial links joining the adjacent rings, and supporting features.
  • the circumferentially expandable serpentine rings each include axial struts joined by crowns, where the crowns act as hinges allowing the struts to spread as the ring opens circumferentially.
  • the axial links join the adjacent serpentine rings by connecting at least some of the crowns on the rings.
  • the supporting features extend between at least some of the adjacent struts of at least some of the serpentine rings, where the supporting features elongate and the struts remain substantially undeformed as the ring circumferentially expands.
  • the endoprosthesis may be constructed from a variety of conventional stent materials and may be either balloon-expandable, self-expanding, or a combination of both.
  • the serpentine rings of the self-expanding endoprostheses will be sufficiently elastic so that they can be constrained in a small cross-sectional area during delivery and released within the vasculature or other body lumens to assume a circumferentially expanded configuration.
  • the serpentine rings of the balloon-expandable endoprostheses will be sufficiently malleable so that they can be circumferentially expanded by applying a radially outward force from within the rings, typically using an inflatable balloon or other expandable structure.
  • Particularly preferred stent materials include metals and alloys such as iron, zinc, steel, cobalt-chromium, nickel-titanium, as well as polymers such as poly lactides, polycaprolactone, polyethylene carbonate, copolymers of polylactide-glycolide, poly lactide-trimethylenecarbonates, and the like. Particular materials and fabrication methods are described in commonly owned application Ser. No. 11/_______ (Attorney Docket No. 022265-000520US), filed on the same day as the present application.
  • the supporting features may have a variety of specific configurations or patterns which are selected to elongate or otherwise expand as the serpentine rings of the endoprosthesis are expanded.
  • Exemplary supporting feature configurations include U-shaped connectors, V-shaped connectors, S-shaped connectors, spiral-shaped connectors, W-shaped connectors, N-shaped connectors, Z-shaped connectors, and the like.
  • the supporting structures may have variable widths, for example the spiral-shaped connectors may include ring or disk-shaped cores to enhance or control the surface area.
  • the width and cross-sectional area of the supporting feature will usually be less than the width and cross-sectional area of the serpentine rings so that expansion of the supporting features does not deform or deflect the main ring structure, it will be possible to increase the area of the supporting feature by providing deflection points which allow the supporting feature to yield preferentially relative to the serpentine rings. For example, portions of the supporting feature may be notched so that they yield first as the endoprosthesis is expanded.
  • one or more additional supporting features may be disposed between at least some of the adjacent struts.
  • a single supporting feature When a single supporting feature is employed, it will usually extend generally between the mid-points on the adjacent struts, but in other instances could be disposed closer to the ends of the struts which are not connected together with a crown.
  • two or more supporting features are provided between adjacent pairs of struts, they may be located at any point along the length of the strut, typically with one being located near the midpoint and another being located near the free ends (i.e., ends which are not joined together with the crown).
  • the axial links will usually comprise short linear beams, where the linear beams are axially aligned with the axis of the endoprosthesis. In other cases, the linear beams may be aligned at a shallow angle relative to the axis, typically from zero degrees to 45 degrees.
  • Endoprostheses may comprise a plurality of circumferentially expandable serpentine rings joined by axial links, where the supporting features extend between at least some adjacent axial links between adjacent serpentine rings. These supporting features between the adjacent axial links elongate as the rings circumferentially expand.
  • Exemplary supporting features which are connected between the adjacent axial links include serpentine connectors, usually where folded portions of the connectors extend into the region between adjacent axial struts.
  • the connectors could comprise “box” connectors having symmetric extending lengths which project into the regions between axial struts.
  • FIG. 1 illustrates a conventional serpentine ring stent.
  • FIGS. 2A and 2B illustrate a first embodiment of the endoprostheses of the present invention having U-shaped connectors between adjacent axial struts in a serpentine ring.
  • FIG. 3 illustrates the stent structure of FIGS. 2A and 2B after expansion.
  • FIGS. 4 and 5 illustrate an exemplary V-shaped connector as the supporting feature where the connector can be oriented toward the crown ( FIG. 4 ) or away from the crown ( FIG. 5 ).
  • FIG. 6 illustrates an exemplary S-shaped connector as the supporting structure.
  • FIGS. 7-9 illustrate exemplary spiral-shaped supporting structures, where FIG. 7 illustrates an everting spiral, FIG. 8 illustrates a spiral having a ring core, and FIG. 9 illustrates a spiral having a disk core.
  • FIG. 10 illustrates an exemplary endoprosthesis structure having U-shaped connectors located near the open ends of the serpentine structure.
  • FIGS. 11 and 12 illustrate exemplary endoprosthesis structures having pairs of supporting features between adjacent axial struts.
  • FIG. 13 illustrates a complex supporting feature having both radially and axially aligned elongating portions.
  • FIGS. 14 , 15 A and 15 B illustrate a U-shaped supporting feature having notch-like yield points which control a two-stage expansion, as shown in FIGS. 15A and 15B .
  • FIGS. 16 and 17 illustrate exemplary endoprosthesis designs where adjacent serpentine rings are connected by angled axial links.
  • FIG. 16 further illustrates an M-shaped connector as the supporting feature while FIG. 17 ; illustrates a N-shaped connector as the supporting feature.
  • FIGS. 18 and 19 illustrate supporting features connecting adjacent axial links, where FIG. 18 illustrates a serpentine pattern, FIG. 19 illustrates a box pattern connector.
  • the present invention provides an endoprosthesis, such as a stent, that is used for treating vascular or other luminal conditions with supporting features or elements added to a base stent structure.
  • the base structure of the stent is formed from one or more serpentine rings.
  • the rings may be interconnected directly or with at least one link.
  • Each ring is composed of multiple expansion segments constructed from crowns and struts.
  • the stent is then reinforced by supporting features that increase radial strength (e.g., hoop strength), increase surface area, and/or reduce recoil compared to the stent without the supporting features.
  • the at least one supporting feature usually connects opposite sides of axial struts which expand (spread apart) about crowns (hinges).
  • the supporting feature may connect axial links which join the serpentine rings. Upon expansion of the segment the supporting feature increases radial strength and/or reduces recoil.
  • the stents may be non-degradable or degradable, where degradation includes biodegradation, bioerosion, bioabsorption, corrosion, and disintegration completely or partially in physiological environment.
  • the supporting feature may undergo plastic deformation upon expansion to reinforce the base structure of the stent or alternatively may elastically expand to provide the reinforcement.
  • the at least one supporting feature undergoes deformation upon expansion and reinforces the base structure of the stent.
  • the at least one supporting feature increases the radial strength of the expanded stent by at least 15%, preferably by at least 50%, more preferably by at least 100% compared to the stent without the at least one supporting feature.
  • the at least one supporting feature provides a stent which recoils after expansion by less than 15%, preferably by less than 7%, more preferably by less than 4%.
  • the at least one supporting feature provides a stent with recoil at least 28 days after expansion in a mammal of less than 20%, preferably less than 10%, more preferably less than 6%.
  • the supporting features will usually connect from strut to strut, but may alternatively or additionally from strut to crown, from strut to link, from link to link, from crown to crown, from crown to link, or from crown to same crown.
  • Exemplary supporting features can contain varying types of shapes such as C-shape, V-shape, U-shape, S-shape, Y-shape, M-shape, W-shape, Z-shape, spiral-shape or other types. These shapes may be continuous or discontinuous. At least one type of supporting feature per ring may be present.
  • the supporting feature thickness and/or width may be greater than, less than or approximately equal to the thickness of the adjacent expansion segment.
  • the supporting feature thickness ranges from 0.125 mm (0.0005 in) to 2.5 mm (0.010 in), preferably 0.25 mm (0.001 in) to 1.25 mm (0.005 in), more preferably 0.5 mm (0.002 in) to 1 mm (0.004 in).
  • the supporting feature width ranges from 0.125 mm (0.0005 in) to 2.5 mm (0.010 in), preferably 0.25 mm (0.001 in) to 1.25 mm (0.005 in), more preferably 0.5 mm (0.002 in) to 1 mm (0.004 in).
  • the path length of the supporting feature ranges from 1.25 mm (0.005 in) to 25 mm (1 in), preferably 0.25 mm (0.010 in) to 0.75 mm (0.250 in), more preferably 0.5 mm (0.020 in) to 2.5 mm (0.100 in).
  • the angle at which the supporting feature connects to the expansion segment or link is approximately 90 degrees, but the angle may alternatively be less than 90 degrees or greater than 90 degrees.
  • the angle at which the supporting feature connects to the axial strut or link ranges from 30 degrees to 150 degrees, preferably 45 to 135 degrees, more preferably 60 to 120 degrees.
  • the material of the supporting feature may be metallic, metal alloy, polymeric, composite, ceramic, or combination thereof, or other type of material, and can be of similar type as the expansion segment or link, or different type.
  • the increase in radial strength and/or reduction of recoil provided by these designs can be of particular benefit for biodegradable stents.
  • the endoprosthesis designs and patterns are applicable to both biodegradable and non-biodegradable materials to provide an enhanced strength and/or increased elasticity.
  • Exemplary biodegradable endoprosthesis materials include metallic, metallic alloy, polymeric, ceramic, composite, as well as other materials in combinations thereof.
  • the yield strength for the biodegradable material(s) will usually be at least 50% of ultimate strength, preferably being at least 75% of ultimate strength, and more preferably being at least 90% of ultimate strength.
  • the yield strength can be measured in water at 37° C.
  • the elastic modulus for biodegradable metallic stents will usually be at least 50 GPa, preferably being at least 100 GPa, and more preferably at least 150 GPa.
  • the elastic modulus of biodegradable polymeric stents in contrast, will be at least 0.5 GPa, preferably being at least 0.75 GPa, and more preferably being at least 1 GPa, measured in water at 37° C. Higher strain at yield may contribute to greater recoil of the stent.
  • the yield strain for biodegradable polymeric stent materials will preferably be no more than 10% when measured in water at 37° C., preferably being no more than 5%, and more preferably being no more than 3%.
  • the plastic strain for the biodegradable polymeric stent materials will preferably be at least 20%, more preferably being at least 30%, and still more preferably being at least 40%, when measured in water at 37° C., while the elastic recovery of the strained biodegradable polymeric stent material is at most 15%, preferably at most 10%, and more preferably at most 5%, when measured in water at 37° C.
  • the biodegradable stent materials may have a widely varying persistence. Usually, the material will substantially degrade within three years after implantation, more usually within one year, and still more usually within six months. When degrading under physiological conditions, such as vascular conditions, after one month the biodegradable stent will preferably retain at least 25% of the hoop strength, preferably maintaining at least 40%, and more preferably maintaining at least 70%.
  • the biodegradable polymeric stent materials may degrade by any of several known mechanisms, including bulk erosion, surface erosion, and combinations thereof.
  • the biodegradable polymeric stent material usually degrades by at least one of hydrolytic degradation, enzymatic degradation, oxidative degradation, photo degradation, degradation under physiological environment or combination thereof.
  • Suitable the biodegradable polymeric stent material includes, but are not limited to, polyesters, polyanhydrides, polyamides, polyurethanes, poly(ester urethane), polyureas, polyethers, polyalkylene carbonates, polyacrylic acids, polyamines, polyester amides, polyester amines, polyvinylacetate, polyethylene imine, polycyanoacrylates, polyphosphazenes, polyphosphates, polyphosphonates, polyurethanes, polyureas, polysulfonates, polysulfonamides, polylactides, polyglycolides, regenerated cellulose, or biopolymers or blends, block polymers, copolymers or combinations thereof.
  • the biodegradable polymeric stent material in this invention can be homopolymers, copolymers, graft polymer, block polymers, polymers with special functional groups or end groups such as acidic or hydrophilic type or a blend of two or more homopolymers or copolymers.
  • the biodegradable polymeric stent material can have varying molecular architecture such as linear, branched, crosslinked, hyperbranched or dendritic.
  • the biodegradable polymeric stent material in this invention can range from 10 KDa to 10,000 KDa in molecular weight, preferably from 100 KDa to 1000 KDa, more preferably 300 KDa to 600 KDa.
  • the biodegradable polymeric stent material incorporates at least one additive.
  • the additives can affect strength, recoil, or degradation rate or combination thereof. Additives can also affect processing of biodegradable stent material, radiopacity or surface roughness or others. Additives can be biodegradable or non-biodegradable.
  • the additives can be incorporated in to the biodegradable stent material by blending, extrusion, injection moulding, coating, surface treatment, chemical treatment, mechanical treatment, stamping, or others or combinations thereof.
  • the additives can be chemically modified prior to incorporation in to the biodegradable stent material.
  • the weight percentage of the additives can range from 0.01% to 25%, preferably 0.1% to 10%, more preferably 1% to 5%.
  • the additive includes at least nanoclay, nanotubes, nanoparticles, exfoliates, fibers, whiskers, platelets, nanopowders, fullerenes, nanosperes, zeolites, polymers or others or combination thereof.
  • nanoclay includes Montmorillonite, Smectites, Talc, or platelet-shaped particles or others or combination thereof.
  • Clays can be intercalated or exfoliated.
  • Example of clays include Cloisite NA, 93A, 30B, 25A, 15A, 10A or others or combination thereof.
  • fibers examples include cellulose fibers such as Linen, cotton, rayon, acetate; proteins fibers such as wool or silk; plant fiber; glass fiber; carbon fiber; metallic fibers; ceramic fibers; absorbable fibers such as polyglycolic acid, polylactic acid, polyglyconate or others.
  • whiskers include hydroxyapetite whiskers, tricalcium phosphate whiskers or others.
  • the additives includes at least modified starch, soybean, hyaluronic acid, hydroxyapatite, tricarbonate phosphate, anionic and cationic surfactants such as sodium docecyl sulphate, triethylene benzylammonium chloride, pro-degradant such as D2W (from Symphony Plastic Technologies), photodegradative additives such as UV-H (from Willow Ridge Plastics), oxidative additives such as PDQ (from Willow Ridge Plastics), TDPA, family of polylactic acid and its random or block copolymers or others.
  • pro-degradant such as D2W (from Symphony Plastic Technologies)
  • photodegradative additives such as UV-H (from Willow Ridge Plastics), oxidative additives such as PDQ (from Willow Ridge Plastics), TDPA, family of polylactic acid and its random or block copolymers or others.
  • the additive can induce degradation of non-degradable polymeric stent material.
  • pro-degradant such as D2W (from Symphony Plastic Technologies)
  • photodegradative additives such as UV-H (from Willow Ridge Plastics), oxidative additives such as PDQ (from Willow Ridge Plastics), TDPA or others or combination thereof
  • UV-H from Willow Ridge Plastics
  • oxidative additives such as PDQ (from Willow Ridge Plastics)
  • TDPA TDPA or others or combination thereof
  • the additives include electroactive or electrolyte polymers, hydroscopic polymers, dessicants, or others.
  • the additive may include an oxidizer such an acids, perchlorates, nitrates, permanganates, salts or other or combination thereof.
  • the additive may include a monomer of the biodegradable polymeric stent material.
  • glycolic acid is an additive to polyglycolic acid or its copolymer stent material.
  • the additive may include water repellent monomers, oligomers or polymers such as bees wax, low MW polyethylene or others.
  • the additive can be water attractant monomers, oligomers or polymers such as polyvinyl alcohol, polyethylene oxide, glycerol, caffeine, lidocaine or other.
  • the additive can affect crystallinity of the biodegradable polymeric stent material.
  • Example of additive of nanoclay to PLLA affects its crystallinity.
  • the biodegradable polymeric stent material can have increased crystallinity upon exposure to radiation such as gamma or ebeam.
  • the cumulative radiation dose can range from 1 Mrad to 100 Mrad, preferably 5 to 50 Mrad, more preferably 10 to 30 Mrad.
  • the biodegradable stent material has increased crystallinity by increasing orientation of polymer chains with in the biodegradable stent material in radial and/or longitudinal direction by drawing, pressurizing and/or heating the stent material. In another embodiment, the drawing, pressurizing and/or heating the stent material occurs simultaneously or sequentially.
  • the stent material may include pharmacological agents, such as immunomodulators, anti-cancer, anti-proliferative, anti-inflammatory, antithrombotic, antiplatelet, antifungal, antidiabetic, antihyperlipidimia, antiangiogenic, angiogenic, antihypertensive, healing promoting drugs, or other therapeutic classes of drugs or combination thereof.
  • pharmacological agents such as immunomodulators, anti-cancer, anti-proliferative, anti-inflammatory, antithrombotic, antiplatelet, antifungal, antidiabetic, antihyperlipidimia, antiangiogenic, angiogenic, antihypertensive, healing promoting drugs, or other therapeutic classes of drugs or combination thereof.
  • Illustrative immunomodulators agents include but are not limited to rapamycin, everolimus, ABT 578, AP20840, AP23841, AP23573, CCl-779, deuterated rapamycin, TAFA93, tacrolimus, cyclosporine, TKB662, myriocin, their analogues, pro-drug, metabolites, slats, or others or combination thereof.
  • Illustrative anticancer agents include acivicin, aclarubicin, acodazole, acronycine, adozelesin, alanosine, aldesleukin, allopurinol sodium, altretamine, aminoglutethimide, amonafide, ampligen, amsacrine, androgens, anguidine, aphidicolin glycinate, asaley, asparaginase, 5-azacitidine, azathioprine, Bacillus calmette-guerin (BCG), Baker's Antifol (soluble), beta-2′-deoxythioguanosine, bisantrene hcl, bleomycin sulfate, busulfan, buthionine sulfoximine, BWA 773U82, BW 502U83.HCl, BW 7U85 mesylate, ceracemide, carbetimer, carboplatin, carmustine, chlorambucil,
  • Illustrative antiinflammatory agents include classic non-steroidal anti-inflammatory drugs (NSAIDS), such as aspirin, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nambumetone (relafen), acetaminophen (Tylenol®), and mixtures thereof, COX-2 inhibitors, such as nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, APHS, etod
  • Analogs, derivatives, prodrugs, salts, synthetic or biologic equivalents of these pharmaceutical agents can be released from the stents depending on the type of treatment needed, such as hyperproliferative diseases, stenosis, wound healing, cancer, aneurysm, diabetic disease, abdominal aortic aneurysm, angiogenesis, hypercalcemia, ischemia, fibrillation, arrhythmia or others.
  • the agents can be released from the implant using non-degradable, partially degradable, fully degradable coatings or a combination as disclosed in prior patent application which is referenced and incorporated in this application in its entirety.
  • the agents can be incorporated as a matrix with the coating or applied on the stent and covered with the coating as a rate limiting barrier, or the drug agent directly coated onto the stent surface.
  • the solvent used to incorporate the agent and the coating on a stent can be an organic solvent such as dichloromethane, tetrahydrofuran, ethanol, or other solvents.
  • the solvent used to coat the agent and/or agent-polymer matrix does not affect the chemical or mechanical properties of the polymeric stent material.
  • supercritical fluids such as supercritical carbon dioxide is used as a carrier solvent for the agent and/or the polymer and coats the stent with agent and/or agent-polymer matrix.
  • non-reactive gas such as carbon dioxide removes the need to use other organic solvents which can alter chemical and physical properties of the pharmacological agent.
  • the crystallinity of the pharmaceutical agent on the stent material is greater than 90%, preferably greater than 93%, more preferably greater than 95%.
  • the pharmacological agent can be incorporated in the biodegradable polymeric stent material and extruded into stent tubing prior to laser cutting of the stent from the tubes.
  • the agent is incorporated in a protective coating to prevent degradation of the agents during extrusion or laser cutting.
  • the rate of agent release can be configured to be release at certain times and for certain durations corresponding to the degradation rate of the stent material or biological response events within the stent material environment.
  • an anti-inflammatory, antiproliferative, or immunomodulator drug or a combination of these can be made to release during the entire degradation period.
  • Multiple drugs can be released to match the degradation rate of the coating and/or degradation rate of the implant.
  • Antiplatelet or anti-thrombotic agents can be released in the initial phase and anti-inflammatory or antiproliferative or immunosuppressants can be released concurrently or at the later phase.
  • a stent 10 has the same base pattern as the stent illustrated in FIG. 1 , including a plurality of adjacent serpentine rings 12 joined by axial links 14 .
  • the stent 10 includes six adjacent serpentine rings 12 , where each ring includes six serpentine segments comprising a pair of axial struts 16 joined by a hinge-like crown 18 at one end.
  • the number of rings and segments may vary widely depending on the size of the desired size of the stent.
  • a supporting feature 20 is disposed between adjacent axial struts 16 and connected so that it will expand, usually elongate, circumferentially with the struts, as shown in FIG. 3 .
  • the supporting features 20 are in a generally closed U-shaped configuration prior to expansion, as shown in FIGS. 2A and 2B , and open into a shallow V-shape along with the opening of the axial struts 16 about the crowns 18 during radial expansion of the serpentine rings 12 , as shown in FIG. 3 .
  • Supporting features 20 enhance the hoop strength of the stent after radial expansion, help resist recoil after expansion is completed, and provide additional area for supporting the vascular or other luminal wall and optionally for delivering drugs into the luminal wall.
  • FIGS. 2A and 2B While U-shaped supporting feature 20 are illustrated in FIGS. 2A and 2B , a variety of other configurations may be utilized, as illustrated in FIGS. 4-17 .
  • V-shaped supporting features 22 are disposed between the adjacent axial struts 16 .
  • the supporting features 24 of FIG. 5 are generally the same as those in FIG. 4 , except they are pointed in the opposite direction, i.e., away from the crowns 18 rather than toward the crowns.
  • S-shaped connectors 26 are illustrated in FIG. 6
  • spiral-shaped connectors 28 are shown in FIG. 7 .
  • FIG. 8 shows an alternative spiral-shaped connector 30 having an open ring at its center
  • FIG. 9 shows a similar supporting feature 32 having a disk at its center.
  • FIG. 12 illustrates a pair of connectors 34 joined near the midpoint
  • FIG. 13 illustrates a complex supporting feature 40 joined between adjacent axial struts 16 at three points, two near the open end of the struts and a third on the inner side of the crown 18 .
  • the supporting features 42 may have deflection points 44 formed along their lengths in order to control expansion.
  • the supporting features may be programmed to first open at the deflection points 44 , as illustrated in FIG. 15A , and to later open at the crown of the connector, as shown in FIG. 15B .
  • Such programmed opening helps assure that the axial struts 16 may expand without being significantly hindered by the forces needed to expand the supporting features 42 .
  • the supporting features 50 may comprise N-shaped connectors while the axial links 52 may be angled relative to the axial direction of the endoprosthesis.
  • N-shaped supporting features 60 may be provided to join serpentine rings held together by angled axial links 62 .
  • the supporting features may also be connected between axial links 14 in the endoprostheses of the present invention.
  • the supporting feature 70 has a generally serpentine configuration with a bent or folded portion extending into the region between adjacent axial struts 16 .
  • the supporting feature 72 in the endoprosthesis of FIG. 19 is similar to 70 , except that the supporting feature includes a box region having a pair of projections 74 extending into the regions between adjacent axial struts 16 .
  • the supporting features 70 and 72 will both enhance the hoop strength of the serpentine ring after radial expansion, inhibit recoil, and provide an enhanced surface area for supporting tissue and delivering active agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • Biological Depolymerization Polymers (AREA)
US12/016,077 2007-01-19 2008-01-17 Endoprosthesis structures having supporting features Abandoned US20080177373A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US12/016,077 US20080177373A1 (en) 2007-01-19 2008-01-17 Endoprosthesis structures having supporting features
US13/536,957 US20130150943A1 (en) 2007-01-19 2012-06-28 Biodegradable endoprostheses and methods for their fabrication
US13/539,770 US8636792B2 (en) 2007-01-19 2012-07-02 Biodegradable endoprostheses and methods for their fabrication
US13/897,302 US8814930B2 (en) 2007-01-19 2013-05-17 Biodegradable endoprosthesis and methods for their fabrication
US14/097,087 US20140188243A1 (en) 2007-01-19 2013-12-04 Biodegradable endoprostheses and methods for their fabrication
US14/461,159 US9119905B2 (en) 2007-01-19 2014-08-15 Biodegradable endoprostheses and methods for their fabrication
US14/604,621 US20160213499A1 (en) 2007-01-19 2015-01-23 Biodegradable endoprostheses and methods for their fabrication
US14/611,043 US20150374521A1 (en) 2008-01-17 2015-01-30 Biodegradable endoprostheses and methods for their fabrication
US14/804,415 US9566371B2 (en) 2007-01-19 2015-07-21 Biodegradable endoprostheses and methods for their fabrication
US15/178,506 US20160278953A1 (en) 2007-01-19 2016-06-09 Biodegradable endoprostheses and methods for their fabrication
US15/420,615 US20170156899A1 (en) 2007-01-19 2017-01-31 Biodegradable endoprostheses and methods for their fabrication
US15/900,404 US20200093619A1 (en) 2007-01-19 2018-02-20 Biodegradable endoprostheses and methods for their fabrication
US17/709,116 US20240074882A1 (en) 2007-01-19 2022-03-30 Biodegradable endoprostheses and methods for their fabrication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88570007P 2007-01-19 2007-01-19
US12/016,077 US20080177373A1 (en) 2007-01-19 2008-01-17 Endoprosthesis structures having supporting features

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/473,354 Continuation-In-Part US8323760B2 (en) 2007-01-19 2012-05-16 Biodegradable endoprostheses and methods for their fabrication

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/016,085 Continuation-In-Part US8182890B2 (en) 2007-01-19 2008-01-17 Biodegradable endoprostheses and methods for their fabrication
US13/434,555 Continuation-In-Part US20120187606A1 (en) 2007-01-19 2012-03-29 Biodegradable endoprostheses and methods for their fabrication
US13/536,957 Continuation-In-Part US20130150943A1 (en) 2007-01-19 2012-06-28 Biodegradable endoprostheses and methods for their fabrication

Publications (1)

Publication Number Publication Date
US20080177373A1 true US20080177373A1 (en) 2008-07-24

Family

ID=39636746

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/016,077 Abandoned US20080177373A1 (en) 2007-01-19 2008-01-17 Endoprosthesis structures having supporting features
US12/016,085 Active 2030-12-21 US8182890B2 (en) 2007-01-19 2008-01-17 Biodegradable endoprostheses and methods for their fabrication
US13/434,555 Abandoned US20120187606A1 (en) 2007-01-19 2012-03-29 Biodegradable endoprostheses and methods for their fabrication
US13/473,354 Active US8323760B2 (en) 2007-01-19 2012-05-16 Biodegradable endoprostheses and methods for their fabrication
US14/450,137 Abandoned US20140350659A1 (en) 2007-01-19 2014-08-01 Biodegradable endoprostheses and methods for their fabrication
US14/945,253 Abandoned US20160067389A1 (en) 2007-01-19 2015-11-18 Biodegradable endoprostheses and methods for their fabrication

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/016,085 Active 2030-12-21 US8182890B2 (en) 2007-01-19 2008-01-17 Biodegradable endoprostheses and methods for their fabrication
US13/434,555 Abandoned US20120187606A1 (en) 2007-01-19 2012-03-29 Biodegradable endoprostheses and methods for their fabrication
US13/473,354 Active US8323760B2 (en) 2007-01-19 2012-05-16 Biodegradable endoprostheses and methods for their fabrication
US14/450,137 Abandoned US20140350659A1 (en) 2007-01-19 2014-08-01 Biodegradable endoprostheses and methods for their fabrication
US14/945,253 Abandoned US20160067389A1 (en) 2007-01-19 2015-11-18 Biodegradable endoprostheses and methods for their fabrication

Country Status (7)

Country Link
US (6) US20080177373A1 (enrdf_load_stackoverflow)
EP (3) EP2783710B1 (enrdf_load_stackoverflow)
JP (8) JP5355420B2 (enrdf_load_stackoverflow)
CN (7) CN105616044A (enrdf_load_stackoverflow)
BR (2) BRPI0806623A2 (enrdf_load_stackoverflow)
ES (1) ES2605731T3 (enrdf_load_stackoverflow)
WO (2) WO2008089446A2 (enrdf_load_stackoverflow)

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080177374A1 (en) * 2007-01-19 2008-07-24 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US20090036964A1 (en) * 2007-08-01 2009-02-05 Prescient Medical, Inc. Expandable Prostheses for Treating Atherosclerotic Lesions Including Vulnerable Plaques
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
US20110022155A1 (en) * 2009-07-21 2011-01-27 Yunbing Wang Biodegradable Stent With Adjustable Degradation Rate
US20110277305A1 (en) * 2007-05-04 2011-11-17 Abbott Cardiovascular Systems Inc. Stents with high radial strength and methods of manufacturing same
US20120158125A1 (en) * 2009-09-16 2012-06-21 Milisav Obradovic Stent having expandable elements
US20120290073A1 (en) * 2011-05-13 2012-11-15 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US8487017B2 (en) 2011-06-27 2013-07-16 Covidien Lp Biodegradable materials for orthopedic devices based on polymer stereocomplexes
US20130211489A1 (en) * 2010-02-10 2013-08-15 Apertomed L.L.C. Methods, Systems and Devices for Treatment of Cerebrospinal Venous Insufficiency and Multiple Sclerosis
US8636792B2 (en) 2007-01-19 2014-01-28 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
CN103948459A (zh) * 2014-05-27 2014-07-30 辽宁生物医学材料研发中心有限公司 一种低回弹高支撑冠状动脉可降解支架
US8814930B2 (en) 2007-01-19 2014-08-26 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
US20150174864A1 (en) * 2011-10-14 2015-06-25 Midsun Group Inc. Self-fusing carbon fiber silicone perforated tape
US9198782B2 (en) 2006-05-30 2015-12-01 Abbott Cardiovascular Systems Inc. Manufacturing process for polymeric stents
US9198785B2 (en) 2010-01-30 2015-12-01 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US9216238B2 (en) 2006-04-28 2015-12-22 Abbott Cardiovascular Systems Inc. Implantable medical device having reduced chance of late inflammatory response
US9259339B1 (en) 2014-08-15 2016-02-16 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9381103B2 (en) * 2014-10-06 2016-07-05 Abbott Cardiovascular Systems Inc. Stent with elongating struts
US9387282B2 (en) 2010-03-31 2016-07-12 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
WO2016164848A1 (en) 2015-04-08 2016-10-13 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9480588B2 (en) 2014-08-15 2016-11-01 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9517149B2 (en) 2004-07-26 2016-12-13 Abbott Cardiovascular Systems Inc. Biodegradable stent with enhanced fracture toughness
US9522503B2 (en) 2006-06-15 2016-12-20 Abbott Cardiovascular Systems Inc. Methods of treatment with stents with enhanced fracture toughness
US9675457B2 (en) 2010-07-27 2017-06-13 Incept, Llc Methods and apparatus for treating neurovascular venous outflow obstruction
US9687594B2 (en) 2009-07-21 2017-06-27 Abbott Cardiovascular Systems Inc. Method of treating with poly(L-lactide) stent with tunable degradation rate
US9730819B2 (en) 2014-08-15 2017-08-15 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
WO2017200956A1 (en) 2016-05-16 2017-11-23 Elixir Medical Corporation Uncaging stent
US9827119B2 (en) * 2010-01-30 2017-11-28 Abbott Cardiovascular Systems Inc. Polymer scaffolds having a low crossing profile
WO2018039444A1 (en) * 2016-08-25 2018-03-01 Mico Innovations, Llc Neurovascular stent
US9908143B2 (en) 2008-06-20 2018-03-06 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US9931231B2 (en) 2014-12-29 2018-04-03 Cook Medical Technologies Llc Support structures for prostheses with branching portions
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
WO2019033121A1 (en) 2017-08-11 2019-02-14 Elixir Medical Corporation RELEASE OF STENT
US10307274B2 (en) 2011-07-29 2019-06-04 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
US10646359B2 (en) 2008-06-20 2020-05-12 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US20200230300A1 (en) * 2009-05-20 2020-07-23 Lyra Therapeutics Inc. Drug-eluting medical implants
US10918505B2 (en) 2016-05-16 2021-02-16 Elixir Medical Corporation Uncaging stent
US11344439B2 (en) * 2018-03-09 2022-05-31 Vesper Medical, Inc. Implantable stent
US11684474B2 (en) 2018-01-25 2023-06-27 Edwards Lifesciences Corporation Delivery system for aided replacement valve recapture and repositioning post-deployment
US11839560B2 (en) 2019-02-28 2023-12-12 Renata Medical, Inc. Growth stent and valve for congenital narrowings
US11931484B2 (en) 2008-06-20 2024-03-19 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof
US12004939B1 (en) 2022-12-09 2024-06-11 Renata Medical, Inc. Transcatheter growth devices and methods for Norwood, Glenn and Fontan therapy
US12201750B2 (en) 2018-11-21 2025-01-21 Hollister Incorporated Hydration solutions containing volatile solutions and medical device products including the same

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597716B2 (en) 2009-06-23 2013-12-03 Abbott Cardiovascular Systems Inc. Methods to increase fracture resistance of a drug-eluting medical device
EP1834606B1 (en) * 2006-03-16 2013-04-24 CID S.p.A. Stents
CN103122132B (zh) 2006-07-20 2016-03-16 奥巴斯尼茨医学公司 用于医疗器械的可生物吸收聚合物组合物
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8252215B2 (en) * 2008-03-31 2012-08-28 Abbott Cardiovascular Systems Inc. Method for fabricating a stent with nucleating agent
US8394317B2 (en) 2008-08-11 2013-03-12 Abbott Cardiovascular Systems Inc. Method of improving fracture toughness of implantable medical devices through annealing
US8372332B2 (en) * 2008-08-11 2013-02-12 Abbott Cardiovascular Systems Inc. Fabricating an implantable medical device from an amorphous or very low crystallinity polymer construct
US8765040B2 (en) 2008-08-11 2014-07-01 Abbott Cardiovascular Systems Inc. Medical device fabrication process including strain induced crystallization with enhanced crystallization
US8337739B2 (en) * 2008-08-12 2012-12-25 Abbott Cardiovascular Systems Inc. Improving fracture toughness of medical devices with a stereocomplex nucleating agent
US9572692B2 (en) * 2009-02-02 2017-02-21 Abbott Cardiovascular Systems Inc. Bioabsorbable stent that modulates plaque geometric morphology and chemical composition
CA2753189A1 (en) 2009-02-21 2010-08-26 Nadya Belcheva Medical devices having activated surfaces
US8147744B2 (en) 2009-04-10 2012-04-03 Abbott Cardiovascular Systems Inc. Method of making a stent formed from crosslinked bioabsorbable polymer
EP2430068A4 (en) * 2009-05-15 2014-07-02 Orbusneich Medical Inc BIORESORBABLE POLYMERIC COMPOSITIONS AND MEDICAL DEVICES
US8119704B2 (en) * 2009-07-21 2012-02-21 Abbott Cardiovascular Systems Inc. Implantable medical device comprising copolymer of L-lactide with improved fracture toughness
US8207240B2 (en) 2009-09-14 2012-06-26 Abbott Cardiovascular Systems Inc Method to minimize molecular weight drop of poly(L-lactide) stent during processing
US20110288223A1 (en) 2010-01-22 2011-11-24 Kannan Rangaramanujam M Supercritical Carbon-Dioxide Processed Biodegradable Polymer Nanocomposites
TWI407942B (zh) * 2010-02-09 2013-09-11 Univ Nat Taiwan 具預防血管狹窄之心血管支架
US8613880B2 (en) * 2010-04-21 2013-12-24 Abbott Cardiovascular Systems Inc. Post electron beam conditioning of polymeric medical devices
EP2415489B1 (de) 2010-08-03 2016-07-06 Biotronik AG Polylactid-beschichtetes Implantat aus einer biokorrodierbaren Magnesiumlegierung
US8539663B2 (en) 2010-08-23 2013-09-24 Abbott Cardiovascular Systems Inc. Reducing crimping damage to polymer scaffold
US20120059451A1 (en) 2010-09-08 2012-03-08 Qiang Zhang Method of Manufacturing a Polymeric Stent Having Reduced Recoil
US8920867B2 (en) * 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US20120158123A1 (en) * 2010-12-15 2012-06-21 Biotronik Ag Polymer stent
WO2012096696A1 (en) 2011-01-12 2012-07-19 Stanford University Composite laminated structures and methods for manufacturing and using the same
JP6505438B2 (ja) * 2011-06-30 2019-04-24 エリクシアー メディカル コーポレイション 生分解性内部人工器官およびその作製方法
US9839537B2 (en) 2012-03-07 2017-12-12 Abbott Cardiovascular Systems Inc. Bioresorbable polymer scaffold treatment of coronary and peripheral artery disease in diabetic patients
WO2013136965A1 (ja) * 2012-03-15 2013-09-19 テルモ株式会社 生体内留置用ステントおよびステントデリバリーシステム
KR101231197B1 (ko) * 2012-09-20 2013-02-07 썬텍 주식회사 고분자 스텐트
GB2512016A (en) 2012-09-24 2014-09-24 Arterius Ltd Methods
US9724219B2 (en) 2012-10-04 2017-08-08 Abbott Cardiovascular Systems Inc. Method of uniform crimping and expansion of medical devices
WO2014153162A1 (en) * 2013-03-14 2014-09-25 Palmaz Scientific, Inc. Monolithic medical device, methods of making and using the same
TWI510225B (zh) * 2013-06-25 2015-12-01 Univ Nat Cheng Kung Stent
US9364350B2 (en) 2013-07-09 2016-06-14 Abbott Cardiovascular Systems Inc. Stent with eased corner feature
HK1216509A1 (zh) 2014-02-04 2016-11-18 Abbott Cardiovascular Systems, Inc. 具有基於novolimus和丙交酯的塗層使得novolimus與塗層具有最小鍵合量的藥物遞送支架或支撐件
JP2016077354A (ja) 2014-10-10 2016-05-16 住友ゴム工業株式会社 プレフィルドシリンジ用ガスケット
WO2016073563A1 (en) 2014-11-04 2016-05-12 Orbusneich Medical, Inc. Progressive flexibility catheter support frame
US10617847B2 (en) 2014-11-04 2020-04-14 Orbusneich Medical Pte. Ltd. Variable flexibility catheter support frame
CN105641751B (zh) * 2016-03-09 2018-11-30 山东中恒碳纤维科技发展有限公司 一种三维编织复合材料假肢及其制备方法
CA3027591C (en) 2016-06-23 2023-08-01 Poly-Med, Inc. Medical implants having managed biodegradation
US10660773B2 (en) 2017-02-14 2020-05-26 Abbott Cardiovascular Systems Inc. Crimping methods for thin-walled scaffolds
WO2018164205A1 (ja) * 2017-03-08 2018-09-13 国立大学法人山口大学 双安定構造を持つ管腔臓器への留置器具
RU2668131C9 (ru) * 2017-03-09 2018-11-21 Акционерное общество "Военно-промышленная корпорация "Научно-производственное объединение машиностроения" Ножка эндопротеза тазобедренного сустава
RU2668132C9 (ru) * 2017-03-09 2018-11-19 Акционерное общество "Военно-промышленная корпорация "Научно-производственное объединение машиностроения" Головка эндопротеза тазобедренного сустава
RU2668130C2 (ru) * 2017-03-09 2018-09-26 Акционерное общество "Военно-промышленная корпорация "Научно-производственное объединение машиностроения" Чашка эндопротеза тазобедренного сустава
RU2669352C9 (ru) * 2017-03-09 2018-11-21 Акционерное общество "Военно-промышленная корпорация "Научно-производственное объединение машиностроения" Имплантат для замещения костных дефектов
WO2018192370A1 (zh) * 2017-04-17 2018-10-25 Oppo广东移动通信有限公司 显示装置、电子设备及显示装置制作方法
CN107137168B (zh) * 2017-06-21 2019-07-05 青岛容商天下网络有限公司 可降解可收回4d打印线型有机人体支架及其使用方法
US10555825B2 (en) 2017-11-09 2020-02-11 Abbott Cardiovascular Systems Inc. Rotation of a medical device during crimping
KR102328579B1 (ko) * 2018-06-11 2021-11-18 주식회사 삼양홀딩스 열 안정성이 향상된 체내 삽입용 생분해성 의료용 장치 및 그 제조 방법
US10967556B2 (en) 2018-06-11 2021-04-06 Abbott Cardiovascular Systems Inc. Uniform expansion of thin-walled scaffolds
WO2020185851A1 (en) * 2019-03-11 2020-09-17 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Anastomosing stent and methods of use
SG11202011848RA (en) 2019-04-29 2020-12-30 Medical And Pharmaceutical Industry Tech And Development Center Medical implant
RU2707551C1 (ru) * 2019-08-02 2019-11-28 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Способ изготовления биоразлагаемого лакопротеза
JP2025510338A (ja) 2022-03-28 2025-04-14 エリクシアー メディカル コーポレイション 拡張可能遠位先端を伴う吸引カテーテル
CN117618160B (zh) * 2024-01-11 2024-04-09 北京迈迪顶峰医疗科技股份有限公司 瓣膜支架、瓣膜支架的加工方法和人工瓣膜

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441483A (en) * 1992-11-16 1995-08-15 Avitall; Boaz Catheter deflection control
US5964798A (en) * 1997-12-16 1999-10-12 Cardiovasc, Inc. Stent having high radial strength
US5980564A (en) * 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US6190405B1 (en) * 1997-05-28 2001-02-20 Gfe Corporation For Research And Development Unlimited Flexible expandable vascular support
US6245103B1 (en) * 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US20010016770A1 (en) * 1997-06-24 2001-08-23 Allen Richard T. Stent with reinforced struts and bimodal deployment
US20010016769A1 (en) * 1997-03-10 2001-08-23 Hikmat Hojeibane Articulated expandable intraluminal stent
US20020161430A1 (en) * 1996-04-26 2002-10-31 Jang G. David Intravascular stent
US20030064097A1 (en) * 1999-11-23 2003-04-03 Patel Mahesh V. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US20030144729A1 (en) * 2002-01-30 2003-07-31 Scimed Life Systems, Inc. Stent with wishbone connectors and serpentine bands
US20030144726A1 (en) * 2002-01-25 2003-07-31 Majercak David C. Stent with enhanced crossability
US6626939B1 (en) * 1997-12-18 2003-09-30 Boston Scientific Scimed, Inc. Stent-graft with bioabsorbable structural support
US20040073290A1 (en) * 2002-10-09 2004-04-15 Scimed Life Systems, Inc. Stent with improved flexibility
US20040098090A1 (en) * 2002-11-14 2004-05-20 Williams Michael S. Polymeric endoprosthesis and method of manufacture
US20040199242A1 (en) * 2001-12-27 2004-10-07 James Hong Hybrid intravascular stent
US20050031704A1 (en) * 2003-08-06 2005-02-10 Angstrom Medica Tricalcium phosphates, their composites, implants incorporating them, and method for their production
US20050070991A1 (en) * 2003-09-29 2005-03-31 Pienknagura Carla Rosa Intravascular stent with extendible end rings
US20050075716A1 (en) * 2000-05-04 2005-04-07 Avantec Vascular Corporation Flexible stent structure
US6896695B2 (en) * 2000-03-15 2005-05-24 Biotronik Mess-Und Therapiegeraete Gmbh & Co. Stent
US20050125051A1 (en) * 2003-12-05 2005-06-09 Scimed Life Systems, Inc. Detachable segment stent
US20050123588A1 (en) * 2003-06-16 2005-06-09 Zhu Yong H. Deployable multifunctional hemostatic agent
US20050232964A1 (en) * 2004-04-14 2005-10-20 Fennimore Roy R Jr Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20060100695A1 (en) * 2002-09-27 2006-05-11 Peacock James C Iii Implantable stent with modified ends
US20060111485A1 (en) * 2004-04-02 2006-05-25 Laghi Aldo A Surface modification of triblock copolymer elastomers
US20060147538A1 (en) * 2003-05-06 2006-07-06 The Queen's University Of Belfast Nanocomposite drug delivery composition
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon
US20060265048A1 (en) * 2005-05-18 2006-11-23 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US20070043427A1 (en) * 2005-08-19 2007-02-22 Medlogics Device Corporation Lumen-supporting stents
US7258697B1 (en) * 2003-12-22 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent with anchors to prevent vulnerable plaque rupture during deployment
US20070225798A1 (en) * 2006-03-23 2007-09-27 Daniel Gregorich Side branch stent
US20070233233A1 (en) * 2006-03-31 2007-10-04 Boston Scientific Scimed, Inc Tethered expansion columns for controlled stent expansion
US20070299505A1 (en) * 2006-06-23 2007-12-27 Boston Scientific Scimed, Inc. Nesting twisting hinge points in a bifurcated petal geometry
US7316710B1 (en) * 2002-12-30 2008-01-08 Advanced Cardiovascular Systems, Inc. Flexible stent

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867190A (en) * 1971-10-18 1975-02-18 American Cyanamid Co Reducing capillarity of polyglycolic acid sutures
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
NL9001984A (nl) 1990-09-10 1992-04-01 Stamicarbon Werkwijze voor het produceren van een voorwerp van een copolymeer van lactide en epsilon-caprolacton voor medische toepassingen.
CA2060635A1 (en) 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
US5741329A (en) 1994-12-21 1998-04-21 Board Of Regents, The University Of Texas System Method of controlling the pH in the vicinity of biodegradable implants
FI98136C (fi) * 1995-09-27 1997-04-25 Biocon Oy Kudosolosuhteissa hajoava materiaali ja menetelmä sen valmistamiseksi
US5670161A (en) 1996-05-28 1997-09-23 Healy; Kevin E. Biodegradable stent
US5922020A (en) * 1996-08-02 1999-07-13 Localmed, Inc. Tubular prosthesis having improved expansion and imaging characteristics
US6033433A (en) * 1997-04-25 2000-03-07 Scimed Life Systems, Inc. Stent configurations including spirals
DE29825178U1 (de) * 1997-04-25 2005-10-06 Boston Scientific Ltd., St. Michael Verbesserte Stentkonfigurationen
US6610764B1 (en) 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
US6293967B1 (en) * 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
EP1020166A1 (en) * 1999-01-12 2000-07-19 Orbus Medical Technologies, Inc. Expandable intraluminal endoprosthesis
US6224803B1 (en) 1999-04-28 2001-05-01 Advanced Cardiovascular Systems, Inc. Method of forming a thin walled member by extrusion and medical device produced thereby
US6540774B1 (en) * 1999-08-31 2003-04-01 Advanced Cardiovascular Systems, Inc. Stent design with end rings having enhanced strength and radiopacity
ATE331487T1 (de) * 2000-03-09 2006-07-15 Design & Performance Cyprus Lt Stent mit hüllenbefestigungen
AU780196B2 (en) * 2000-03-13 2005-03-10 Kabushiki Kaisha Kyoto Iryo Sekkei Wire rods for vascular stents and vascular stents with the use of the same
US6527801B1 (en) 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
AU2001267075A1 (en) * 2000-06-13 2001-12-24 Scimed Life Systems, Inc. Disintegrating stent and method of making same
US20020161168A1 (en) * 2000-10-27 2002-10-31 Shalaby Shalaby W. Amorphous polymeric polyaxial initiators and compliant crystalline copolymers therefrom
US20030033007A1 (en) 2000-12-22 2003-02-13 Avantec Vascular Corporation Methods and devices for delivery of therapeutic capable agents with variable release profile
US6607548B2 (en) 2001-05-17 2003-08-19 Inion Ltd. Resorbable polymer compositions
US6585755B2 (en) 2001-06-29 2003-07-01 Advanced Cardiovascular Polymeric stent suitable for imaging by MRI and fluoroscopy
CN2517403Y (zh) * 2001-07-27 2002-10-23 微创医疗器械(上海)有限公司 非均一波形结构的冠状动脉支架
CN1131074C (zh) 2001-08-10 2003-12-17 中国人民解放军总医院 一种用于微创快速血管吻合技术的速溶支架的制备方法
US6997944B2 (en) * 2001-08-13 2006-02-14 Advanced Cardiovascular Systems, Inc. Apparatus and method for decreasing stent gap size
WO2003034944A1 (de) * 2001-10-15 2003-05-01 Hemoteq Gmbh Beschichtung von stents zur verhinderung von restenose
US7572287B2 (en) 2001-10-25 2009-08-11 Boston Scientific Scimed, Inc. Balloon expandable polymer stent with reduced elastic recoil
CN2532867Y (zh) * 2002-03-22 2003-01-29 维科医疗器械(苏州)有限公司 零短缩结构冠状动脉扩张支架
EP1501424B1 (en) 2002-04-18 2018-06-06 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Biodegradable shape memory polymeric sutures
US7261734B2 (en) 2002-04-23 2007-08-28 Boston Scientific Scimed, Inc. Resorption-controllable medical implants
JP3988619B2 (ja) * 2002-10-31 2007-10-10 東レ株式会社 ポリ乳酸系樹脂組成物およびそれからなる成形品
US20050187615A1 (en) 2004-02-23 2005-08-25 Williams Michael S. Polymeric endoprostheses with enhanced strength and flexibility and methods of manufacture
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
US6863757B1 (en) 2002-12-19 2005-03-08 Advanced Cardiovascular Systems, Inc. Method of making an expandable medical device formed of a compacted porous polymeric material
US6932930B2 (en) * 2003-03-10 2005-08-23 Synecor, Llc Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same
US7112216B2 (en) * 2003-05-28 2006-09-26 Boston Scientific Scimed, Inc. Stent with tapered flexibility
US6979348B2 (en) * 2003-06-04 2005-12-27 Medtronic Vascular, Inc. Reflowed drug-polymer coated stent and method thereof
BRPI0411431B8 (pt) * 2003-06-13 2021-06-22 Gkss Forschungszentrum Geesthacht Gmbh stents biodegradáveis
KR20060028695A (ko) * 2003-06-16 2006-03-31 난양 테크놀러지컬 유니버시티 고분자 스텐트 및 이의 제조 방법
JP4805148B2 (ja) * 2003-07-18 2011-11-02 ボストン サイエンティフィック リミテッド 医療器具
US7377939B2 (en) 2003-11-19 2008-05-27 Synecor, Llc Highly convertible endolumenal prostheses and methods of manufacture
CN1242818C (zh) * 2003-12-08 2006-02-22 华中科技大学 一种可降解的复合支架材料及其制备方法
DE10361940A1 (de) 2003-12-24 2005-07-28 Restate Patent Ag Degradationssteuerung biodegradierbarer Implantate durch Beschichtung
ATE442822T1 (de) * 2004-04-02 2009-10-15 Arterial Remodelling Technolog Stentanordnung auf polymerbasis
JP2005298617A (ja) * 2004-04-09 2005-10-27 Mitsubishi Plastics Ind Ltd 射出成形体
CN1569270B (zh) 2004-04-29 2011-06-29 上海瑞邦生物材料有限公司 一种表面设有药物涂层的心血管支架的制备方法
US20050261757A1 (en) * 2004-05-21 2005-11-24 Conor Medsystems, Inc. Stent with contoured bridging element
US7971333B2 (en) 2006-05-30 2011-07-05 Advanced Cardiovascular Systems, Inc. Manufacturing process for polymetric stents
US8268228B2 (en) 2007-12-11 2012-09-18 Abbott Cardiovascular Systems Inc. Method of fabricating stents from blow molded tubing
US8747879B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device to reduce chance of late inflammatory response
US8747878B2 (en) 2006-04-28 2014-06-10 Advanced Cardiovascular Systems, Inc. Method of fabricating an implantable medical device by controlling crystalline structure
US7731890B2 (en) 2006-06-15 2010-06-08 Advanced Cardiovascular Systems, Inc. Methods of fabricating stents with enhanced fracture toughness
US7875233B2 (en) 2004-09-30 2011-01-25 Advanced Cardiovascular Systems, Inc. Method of fabricating a biaxially oriented implantable medical device
CN2768714Y (zh) * 2004-11-22 2006-04-05 微创医疗器械(上海)有限公司 一种柔软的血管支架
JP4820551B2 (ja) * 2005-01-14 2011-11-24 テルモ株式会社 生体内留置物
US8420113B2 (en) * 2005-02-10 2013-04-16 Cordis Corporation Biodegradable medical devices with enhanced mechanical strength and pharmacological functions
US20060193891A1 (en) * 2005-02-25 2006-08-31 Robert Richard Medical devices and therapeutic delivery devices composed of bioabsorbable polymers produced at room temperature, method of making the devices, and a system for making the devices
US7622070B2 (en) 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US20070132155A1 (en) 2005-12-13 2007-06-14 Robert Burgermeister Polymeric stent having modified molecular structures in selected regions of the hoops and method for increasing elongation at break
US20070200271A1 (en) 2006-02-24 2007-08-30 Vipul Dave Implantable device prepared from melt processing
US7594928B2 (en) * 2006-05-17 2009-09-29 Boston Scientific Scimed, Inc. Bioabsorbable stents with reinforced filaments
US20070290412A1 (en) 2006-06-19 2007-12-20 John Capek Fabricating a stent with selected properties in the radial and axial directions
US9072820B2 (en) 2006-06-26 2015-07-07 Advanced Cardiovascular Systems, Inc. Polymer composite stent with polymer particles
US20080001330A1 (en) 2006-06-28 2008-01-03 Bin Huang Fabricating polymer stents with injection molding
US7740791B2 (en) 2006-06-30 2010-06-22 Advanced Cardiovascular Systems, Inc. Method of fabricating a stent with features by blow molding
US9089627B2 (en) 2006-07-11 2015-07-28 Abbott Cardiovascular Systems Inc. Stent fabricated from polymer composite toughened by a dispersed phase
US7794495B2 (en) 2006-07-17 2010-09-14 Advanced Cardiovascular Systems, Inc. Controlled degradation of stents
US9265866B2 (en) 2006-08-01 2016-02-23 Abbott Cardiovascular Systems Inc. Composite polymeric and metallic stent with radiopacity
US20080033540A1 (en) 2006-08-01 2008-02-07 Yunbing Wang Methods to prepare polymer blend implantable medical devices
US7923022B2 (en) 2006-09-13 2011-04-12 Advanced Cardiovascular Systems, Inc. Degradable polymeric implantable medical devices with continuous phase and discrete phase
EP2076211A4 (en) 2006-10-20 2015-07-22 Elixir Medical Corp LUMINOUS PROSTHESES AND METHODS OF COATING THEREOF
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
US20080177373A1 (en) 2007-01-19 2008-07-24 Elixir Medical Corporation Endoprosthesis structures having supporting features
US8002817B2 (en) 2007-05-04 2011-08-23 Abbott Cardiovascular Systems Inc. Stents with high radial strength and methods of manufacturing same
US7829008B2 (en) 2007-05-30 2010-11-09 Abbott Cardiovascular Systems Inc. Fabricating a stent from a blow molded tube
US7666342B2 (en) 2007-06-29 2010-02-23 Abbott Cardiovascular Systems Inc. Method of manufacturing a stent from a polymer tube
US7824601B1 (en) 2007-11-14 2010-11-02 Abbott Cardiovascular Systems Inc. Process of making a tubular implantable medical device

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441483A (en) * 1992-11-16 1995-08-15 Avitall; Boaz Catheter deflection control
US20020161430A1 (en) * 1996-04-26 2002-10-31 Jang G. David Intravascular stent
US20010016769A1 (en) * 1997-03-10 2001-08-23 Hikmat Hojeibane Articulated expandable intraluminal stent
US6190405B1 (en) * 1997-05-28 2001-02-20 Gfe Corporation For Research And Development Unlimited Flexible expandable vascular support
US6773455B2 (en) * 1997-06-24 2004-08-10 Advanced Cardiovascular Systems, Inc. Stent with reinforced struts and bimodal deployment
US20010016770A1 (en) * 1997-06-24 2001-08-23 Allen Richard T. Stent with reinforced struts and bimodal deployment
US6719934B2 (en) * 1997-08-01 2004-04-13 Boston Scientific Scimed, Inc. Process for making bioabsorbable self-expanding stent
US6997948B2 (en) * 1997-08-01 2006-02-14 Boston Scientific Scimed, Inc. Bioabsorbable self-expanding stent
US5980564A (en) * 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US20060129222A1 (en) * 1997-08-01 2006-06-15 Stinson Jonathan S Bioabsorbable self-expanding stent
US6652582B1 (en) * 1997-08-01 2003-11-25 Boston Scientific Scimed, Inc. Bioabsorbable endoprosthesis having porosity for by-product collection
US6245103B1 (en) * 1997-08-01 2001-06-12 Schneider (Usa) Inc Bioabsorbable self-expanding stent
US7279005B2 (en) * 1997-08-01 2007-10-09 Boston Scientific Scimed, Inc. Bioabsorbable self-expanding stent
US5964798A (en) * 1997-12-16 1999-10-12 Cardiovasc, Inc. Stent having high radial strength
US6626939B1 (en) * 1997-12-18 2003-09-30 Boston Scientific Scimed, Inc. Stent-graft with bioabsorbable structural support
US7108716B2 (en) * 1997-12-18 2006-09-19 Schneider (Usa) Inc. Stent-graft with bioabsorbable structural support
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US20030064097A1 (en) * 1999-11-23 2003-04-03 Patel Mahesh V. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US6896695B2 (en) * 2000-03-15 2005-05-24 Biotronik Mess-Und Therapiegeraete Gmbh & Co. Stent
US20050075716A1 (en) * 2000-05-04 2005-04-07 Avantec Vascular Corporation Flexible stent structure
US20030088307A1 (en) * 2001-11-05 2003-05-08 Shulze John E. Potent coatings for stents
US20040199242A1 (en) * 2001-12-27 2004-10-07 James Hong Hybrid intravascular stent
US20030144726A1 (en) * 2002-01-25 2003-07-31 Majercak David C. Stent with enhanced crossability
US20030144729A1 (en) * 2002-01-30 2003-07-31 Scimed Life Systems, Inc. Stent with wishbone connectors and serpentine bands
US7354450B2 (en) * 2002-01-30 2008-04-08 Boston Scientific Scimed, Inc. Stent with wishbone connectors and serpentine bands
US20060100695A1 (en) * 2002-09-27 2006-05-11 Peacock James C Iii Implantable stent with modified ends
US20040073290A1 (en) * 2002-10-09 2004-04-15 Scimed Life Systems, Inc. Stent with improved flexibility
US20040098090A1 (en) * 2002-11-14 2004-05-20 Williams Michael S. Polymeric endoprosthesis and method of manufacture
US7316710B1 (en) * 2002-12-30 2008-01-08 Advanced Cardiovascular Systems, Inc. Flexible stent
US20060147538A1 (en) * 2003-05-06 2006-07-06 The Queen's University Of Belfast Nanocomposite drug delivery composition
US20050123588A1 (en) * 2003-06-16 2005-06-09 Zhu Yong H. Deployable multifunctional hemostatic agent
US20050031704A1 (en) * 2003-08-06 2005-02-10 Angstrom Medica Tricalcium phosphates, their composites, implants incorporating them, and method for their production
US20050070991A1 (en) * 2003-09-29 2005-03-31 Pienknagura Carla Rosa Intravascular stent with extendible end rings
US20050125051A1 (en) * 2003-12-05 2005-06-09 Scimed Life Systems, Inc. Detachable segment stent
US7258697B1 (en) * 2003-12-22 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent with anchors to prevent vulnerable plaque rupture during deployment
US20060111485A1 (en) * 2004-04-02 2006-05-25 Laghi Aldo A Surface modification of triblock copolymer elastomers
US20050232964A1 (en) * 2004-04-14 2005-10-20 Fennimore Roy R Jr Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon
US20060265048A1 (en) * 2005-05-18 2006-11-23 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US7291166B2 (en) * 2005-05-18 2007-11-06 Advanced Cardiovascular Systems, Inc. Polymeric stent patterns
US20070043427A1 (en) * 2005-08-19 2007-02-22 Medlogics Device Corporation Lumen-supporting stents
US20070225798A1 (en) * 2006-03-23 2007-09-27 Daniel Gregorich Side branch stent
US20070233233A1 (en) * 2006-03-31 2007-10-04 Boston Scientific Scimed, Inc Tethered expansion columns for controlled stent expansion
US20070299505A1 (en) * 2006-06-23 2007-12-27 Boston Scientific Scimed, Inc. Nesting twisting hinge points in a bifurcated petal geometry

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064982B2 (en) 2001-06-27 2018-09-04 Abbott Cardiovascular Systems Inc. PDLLA stent coating
US9517149B2 (en) 2004-07-26 2016-12-13 Abbott Cardiovascular Systems Inc. Biodegradable stent with enhanced fracture toughness
US9216238B2 (en) 2006-04-28 2015-12-22 Abbott Cardiovascular Systems Inc. Implantable medical device having reduced chance of late inflammatory response
US9198782B2 (en) 2006-05-30 2015-12-01 Abbott Cardiovascular Systems Inc. Manufacturing process for polymeric stents
US9554925B2 (en) 2006-05-30 2017-01-31 Abbott Cardiovascular Systems Inc. Biodegradable polymeric stents
US10390979B2 (en) 2006-05-30 2019-08-27 Advanced Cardiovascular Systems, Inc. Manufacturing process for polymeric stents
US9522503B2 (en) 2006-06-15 2016-12-20 Abbott Cardiovascular Systems Inc. Methods of treatment with stents with enhanced fracture toughness
US8636792B2 (en) 2007-01-19 2014-01-28 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US8323760B2 (en) 2007-01-19 2012-12-04 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US9566371B2 (en) * 2007-01-19 2017-02-14 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US8182890B2 (en) 2007-01-19 2012-05-22 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US20150320577A1 (en) * 2007-01-19 2015-11-12 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US20080177374A1 (en) * 2007-01-19 2008-07-24 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US8814930B2 (en) 2007-01-19 2014-08-26 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
US20150025619A1 (en) * 2007-01-19 2015-01-22 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US9119905B2 (en) * 2007-01-19 2015-09-01 Elixir Medical Corporation Biodegradable endoprostheses and methods for their fabrication
US20110277305A1 (en) * 2007-05-04 2011-11-17 Abbott Cardiovascular Systems Inc. Stents with high radial strength and methods of manufacturing same
US20090036964A1 (en) * 2007-08-01 2009-02-05 Prescient Medical, Inc. Expandable Prostheses for Treating Atherosclerotic Lesions Including Vulnerable Plaques
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
US10646359B2 (en) 2008-06-20 2020-05-12 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US10893960B2 (en) 2008-06-20 2021-01-19 Razmodics Llc Stent fabrication via tubular casting processes
US9908143B2 (en) 2008-06-20 2018-03-06 Amaranth Medical Pte. Stent fabrication via tubular casting processes
US11931484B2 (en) 2008-06-20 2024-03-19 Razmodics Llc Composite stent having multi-axial flexibility and method of manufacture thereof
US20200230300A1 (en) * 2009-05-20 2020-07-23 Lyra Therapeutics Inc. Drug-eluting medical implants
US9844612B2 (en) 2009-07-21 2017-12-19 Abbott Cardiovascular Systems Inc. Method of making a poly(L-lactide) stent with tunable degradation rate
US9889238B2 (en) * 2009-07-21 2018-02-13 Abbott Cardiovascular Systems Inc. Biodegradable stent with adjustable degradation rate
US20110022155A1 (en) * 2009-07-21 2011-01-27 Yunbing Wang Biodegradable Stent With Adjustable Degradation Rate
US9687594B2 (en) 2009-07-21 2017-06-27 Abbott Cardiovascular Systems Inc. Method of treating with poly(L-lactide) stent with tunable degradation rate
US8852268B2 (en) * 2009-09-16 2014-10-07 Bentley Surgical Gmbh Stent having expandable elements
US20120158125A1 (en) * 2009-09-16 2012-06-21 Milisav Obradovic Stent having expandable elements
US9867728B2 (en) 2010-01-30 2018-01-16 Abbott Cardiovascular Systems Inc. Method of making a stent
US11324614B2 (en) 2010-01-30 2022-05-10 Abbott Cardiovascular Systems Inc. Balloon expanded polymer stent
US10123894B2 (en) 2010-01-30 2018-11-13 Abbott Cardiovascular Systems Inc. Method of crimping stent on catheter delivery assembly
US9198785B2 (en) 2010-01-30 2015-12-01 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US9827119B2 (en) * 2010-01-30 2017-11-28 Abbott Cardiovascular Systems Inc. Polymer scaffolds having a low crossing profile
US9763818B2 (en) 2010-01-30 2017-09-19 Abbott Cardiovascular Systems Inc. Method of crimping stent on catheter delivery assembly
US9770351B2 (en) 2010-01-30 2017-09-26 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US20130211489A1 (en) * 2010-02-10 2013-08-15 Apertomed L.L.C. Methods, Systems and Devices for Treatment of Cerebrospinal Venous Insufficiency and Multiple Sclerosis
US10076591B2 (en) 2010-03-31 2018-09-18 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US9387282B2 (en) 2010-03-31 2016-07-12 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US9675457B2 (en) 2010-07-27 2017-06-13 Incept, Llc Methods and apparatus for treating neurovascular venous outflow obstruction
US10779947B2 (en) 2010-07-27 2020-09-22 Incept, Llc Methods and apparatus for treating neurovascular venous outflow obstruction
US11806238B2 (en) 2010-07-27 2023-11-07 Incept, Llc Methods and apparatus for treating neurovascular venous outflow obstruction
US20120290073A1 (en) * 2011-05-13 2012-11-15 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US8545546B2 (en) * 2011-05-13 2013-10-01 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US8487017B2 (en) 2011-06-27 2013-07-16 Covidien Lp Biodegradable materials for orthopedic devices based on polymer stereocomplexes
US10307274B2 (en) 2011-07-29 2019-06-04 Abbott Cardiovascular Systems Inc. Methods for uniform crimping and deployment of a polymer scaffold
US20150174864A1 (en) * 2011-10-14 2015-06-25 Midsun Group Inc. Self-fusing carbon fiber silicone perforated tape
CN103948459A (zh) * 2014-05-27 2014-07-30 辽宁生物医学材料研发中心有限公司 一种低回弹高支撑冠状动脉可降解支架
US9480588B2 (en) 2014-08-15 2016-11-01 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US20180360628A1 (en) * 2014-08-15 2018-12-20 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9855156B2 (en) 2014-08-15 2018-01-02 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9259339B1 (en) 2014-08-15 2016-02-16 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9730819B2 (en) 2014-08-15 2017-08-15 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9381103B2 (en) * 2014-10-06 2016-07-05 Abbott Cardiovascular Systems Inc. Stent with elongating struts
US9931231B2 (en) 2014-12-29 2018-04-03 Cook Medical Technologies Llc Support structures for prostheses with branching portions
WO2016164848A1 (en) 2015-04-08 2016-10-13 Elixir Medical Corporation Biodegradable endoprostheses and methods of their fabrication
US9943426B2 (en) 2015-07-15 2018-04-17 Elixir Medical Corporation Uncaging stent
US10786374B2 (en) 2016-05-16 2020-09-29 Elixir Medical Corporation Uncaging stent
WO2017200956A1 (en) 2016-05-16 2017-11-23 Elixir Medical Corporation Uncaging stent
US12011378B2 (en) 2016-05-16 2024-06-18 Elixir Medical Corporation Uncaging stent
US10271976B2 (en) 2016-05-16 2019-04-30 Elixir Medical Corporation Uncaging stent
US10918505B2 (en) 2016-05-16 2021-02-16 Elixir Medical Corporation Uncaging stent
EP3861961A1 (en) 2016-05-16 2021-08-11 Elixir Medical Corporation Uncaging stent
US10076431B2 (en) 2016-05-16 2018-09-18 Elixir Medical Corporation Uncaging stent
US10383750B1 (en) 2016-05-16 2019-08-20 Elixir Medical Corporation Uncaging stent
US11622872B2 (en) * 2016-05-16 2023-04-11 Elixir Medical Corporation Uncaging stent
WO2018039444A1 (en) * 2016-08-25 2018-03-01 Mico Innovations, Llc Neurovascular stent
EP4450031A2 (en) 2017-08-11 2024-10-23 Elixir Medical Corporation Uncaging stent
WO2019033121A1 (en) 2017-08-11 2019-02-14 Elixir Medical Corporation RELEASE OF STENT
US11684474B2 (en) 2018-01-25 2023-06-27 Edwards Lifesciences Corporation Delivery system for aided replacement valve recapture and repositioning post-deployment
US11344439B2 (en) * 2018-03-09 2022-05-31 Vesper Medical, Inc. Implantable stent
US11980555B2 (en) 2018-03-09 2024-05-14 Vesper Medical, Inc. Implantable stent
US12201750B2 (en) 2018-11-21 2025-01-21 Hollister Incorporated Hydration solutions containing volatile solutions and medical device products including the same
US11839560B2 (en) 2019-02-28 2023-12-12 Renata Medical, Inc. Growth stent and valve for congenital narrowings
US12076256B2 (en) 2019-02-28 2024-09-03 Renata Medical, Inc. Growth stent and valve for congenital narrowings
US12004939B1 (en) 2022-12-09 2024-06-11 Renata Medical, Inc. Transcatheter growth devices and methods for Norwood, Glenn and Fontan therapy
US12208002B2 (en) 2022-12-09 2025-01-28 Renata Medical, Inc. Transcatheter growth devices and methods for Norwood, Glenn and Fontan therapy
US12343249B2 (en) 2022-12-09 2025-07-01 Renata Medical, Inc. Transcatheter growth devices and methods for Norwood, Glenn and Fontan therapy

Also Published As

Publication number Publication date
CN104042375A (zh) 2014-09-17
EP2124816A4 (en) 2013-01-23
CN104042375B (zh) 2016-08-24
WO2008089434A2 (en) 2008-07-24
US20120226345A1 (en) 2012-09-06
JP2010516348A (ja) 2010-05-20
WO2008089446A2 (en) 2008-07-24
EP2783710A1 (en) 2014-10-01
CN101621971A (zh) 2010-01-06
EP2124816B1 (en) 2016-09-28
JP5489725B2 (ja) 2014-05-14
JP2015071056A (ja) 2015-04-16
EP2124816B2 (en) 2019-08-14
WO2008089434A3 (en) 2008-10-09
US8323760B2 (en) 2012-12-04
JP5762486B2 (ja) 2015-08-12
CN104127270A (zh) 2014-11-05
CN101636126A (zh) 2010-01-27
JP2016221352A (ja) 2016-12-28
ES2605731T3 (es) 2017-03-16
EP2109416A4 (en) 2014-06-11
CN104096271B (zh) 2015-12-30
CN105616044A (zh) 2016-06-01
JP2017035511A (ja) 2017-02-16
JP2014195734A (ja) 2014-10-16
US20080177374A1 (en) 2008-07-24
JP5749296B2 (ja) 2015-07-15
US20120187606A1 (en) 2012-07-26
CN101636126B (zh) 2014-06-04
BRPI0806617A2 (pt) 2011-09-20
US8182890B2 (en) 2012-05-22
JP2010516347A (ja) 2010-05-20
JP5355420B2 (ja) 2013-11-27
US20160067389A1 (en) 2016-03-10
WO2008089446A3 (en) 2008-10-09
JP2013188588A (ja) 2013-09-26
EP2783710B1 (en) 2018-08-29
EP2124816A2 (en) 2009-12-02
CN104096271A (zh) 2014-10-15
JP2014014698A (ja) 2014-01-30
US20140350659A1 (en) 2014-11-27
BRPI0806623A2 (pt) 2011-09-13
CN105534627A (zh) 2016-05-04
EP2109416A2 (en) 2009-10-21

Similar Documents

Publication Publication Date Title
US20080177373A1 (en) Endoprosthesis structures having supporting features
US20190070334A1 (en) Luminal prostheses and methods for coating thereof
US10350093B2 (en) Degradable implantable medical devices
EP2726015B1 (en) Biodegradable endoprostheses and methods for their fabrication
JP5456272B2 (ja) 抗血栓剤複合体を含有する医療用具用コーティング
US8636792B2 (en) Biodegradable endoprostheses and methods for their fabrication
US8814930B2 (en) Biodegradable endoprosthesis and methods for their fabrication
US20160278953A1 (en) Biodegradable endoprostheses and methods for their fabrication
AU2015252144A1 (en) Degradable implantable medical devices
AU2014200856A1 (en) Degradable implantable medical devices

Legal Events

Date Code Title Description
AS Assignment

Owner name: ELIXIR MEDICAL CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUANG, HOWARD;YAN, JOHN;CRYER, BRETT;AND OTHERS;REEL/FRAME:020636/0561;SIGNING DATES FROM 20080304 TO 20080305

AS Assignment

Owner name: ELIXIR MEDICAL CORPORATION, A CALIFORNIA CORPORATI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ELIXIR MEDICAL CORPORATION, A DELAWARE CORPORATION;REEL/FRAME:032907/0038

Effective date: 20140502

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION